Role of functional magnetic resonance imaging in assessing metastatic leiomyosarcoma response to chemoembolization

Journal of Computer Assisted Tomography

Volumn 32, Issue 3, 2008, Pages 347-352

  Vossen, Josephina A ^a   Kamel, Ihab R ^a   Buijs, Manon ^a   Liapi, Eleni ^a   Georgiades, Christos S ^a   Hong, Kelvin ^a   Geschwind, Jean Francois H ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Metastatic leiomyosarcoma; MR diffusion imaging; MR perfusion imaging; Transarterial chemoembolization; Treatment response

Indexed keywords

CELL DEATH; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATIENT TREATMENT; SURFACE DIFFUSION;

DIFFUSION IMAGING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; LEIOMYOSARCOMA; MAGNETIC RESONANCE DIFFUSION IMAGING; MAGNETIC RESONANCE PERFUSION IMAGING; MAGNETIC RESONANCE PERFUSIONS; METASTATIC LEIOMYOSARCOMA; PERFUSION IMAGING; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT RESPONSE;

TUMORS;

CISPLATIN; DOXORUBICIN; GADODIAMIDE; IODINATED POPPYSEED OIL; MITOMYCIN C;

ADULT; AGED; ARTICLE; BREATH HOLDING; CANCER CHEMOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DRUG FATALITY; ECHO PLANAR IMAGING; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LEIOMYOSARCOMA; LIVER ABSCESS; LIVER METASTASIS; MALE; MUSCLE; PERCUTANEOUS DRAINAGE; PRIORITY JOURNAL; SPLEEN; THREE DIMENSIONAL IMAGING; TREATMENT RESPONSE; COMPARATIVE STUDY; FOLLOW UP; LIVER TUMOR; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; NUCLEAR MAGNETIC RESONANCE IMAGING; SOFT TISSUE TUMOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEIOMYOSARCOMA; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SOFT TISSUE NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 45849146147     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/RCT.0b013e318134ecd6     Document Type: Article

References (32)

1. Coindre JM, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001;91:1914-1926.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
3. Jaques DP, Coit DG, Casper ES, et al. Hepatic metastases from soft-tissue sarcoma. Ann Surg. 1995;221:392-397.
4. DeMatteo RP, Shah A, Fong Y, et al. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg. 2001;234:540-547. discussion 547-578.
5. Lang H, Nussbaum KT, Kaudel P, et al. Hepatic metastases from leiomyosarcoma: a single-center experience with 34 liver resections during a 15-year period. Ann Surg. 2000;231:500-505.
6. Ng EH, Pollock RE, Romsdahl MM. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer. 1992;69: 1334-1341.
7. Mavligit GM, Zukwiski AA, Ellis LM, et al. Gastrointestinal leiomyosarcoma metastatic to the liver. Durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine. Cancer. 1995;75:2083-2088.
8. Trevisani F, De Notariis S, Rossi C, et al. Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies? J Clin Gastroenterol. 2001;32:383-389.
9. Johnson PJ, Kalayci C, Dobbs N, et al. Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. J Hepatol. 1991;13:120-127.
10. Raoul JL, Heresbach D, Bretagne JF, et al. Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer. 1992;70:585-590.
11. Ramsey DE, Geschwind JF. Chemoembolization of hepatocellular carcinoma - what to tell the skeptics: review and meta-analysis. Tech Vasc Interv Radiol. 2002;5:122-126.
12. Imaeda T, Yamawaki Y, Seki M, et al. Lipiodol retention and massive necrosis after lipiodol-chemoembolization of hepatocellular carcinoma: correlation between computed tomography and histopathology. Cardiovasc Intervent Radiol. 1993;16:209-213.
13. De Santis M, Alborino S, Tartoni PL, et al. Effects of lipiodol retention on MRI signal intensity from hepatocellular carcinoma and surrounding liver treated by chemoembolization. Eur Radiol. 1997;7:10-16.
14. Kuszyk BS, Boitnott JK, Choti MA, et al. Local tumor recurrence following hepatic cryoablation: radiologic-histopathologic correlation in a rabbit model. Radiology. 2000;217:477-486.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
16. Galons JP, Altbach MI, Paine-Murrieta GD, et al. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia. 1999;1:113-117.
17. Geschwind JF, Artemov D, Abraham S, et al. Chemoembolization of liver tumor in a rabbit model: assessment of tumor cell death with diffusion-weighted MR imaging and histologic analysis. J Vasc Interv Radiol.2000;11:1245- 1255.
18. Mardor Y, Pfeffer R, Spiegelmann R, et al. Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging. J Clin Oncol.2003;21:1094-1100.
19. Kamel IR, Bluemke DA, Ramsey D, et al. Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol. 2003;181:708-710.
20. Kamel IR, Bluemke DA, Eng J, et al. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol.2006;17: 505-512.
21. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-1739.
22. Li XP, Meng ZQ, Guo WJ, et al. Treatment for liver metastases from breast cancer: results and prognostic factors. World J Gastroenterol. 2005;11:3782-3787.
23. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-1171.
24. Choi BI, Kim HC, Han JK, et al. Therapeutic effect of transcatheter oily chemoembolization therapy for encapsulated nodular hepatocellular carcinoma: CT and pathologic findings. Radiology. 1992;182: 709-713.
25. Nakamura H, Hashimoto T, Oi H, et al. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology. 1989;170(pt 1): 783-786.
26. Murakami T, Nakamura H, Hori S, et al. Detection of viable tumor cells in hepatocellular carcinoma following transcatheter arterial chemoembolization with iodized oil. Pathologic correlation with dynamic turbo-FLASH MR imaging with Gd-DTPA. Acta Radiol. 1993;34:399-403.
27. Castrucci M, Sironi S, De Cobelli F, et al. Plain and gadolinium-DTPA - enhanced MR imaging of hepatocellular carcinoma treated with transarterial chemoembolization. Abdom Imaging. 1996;21:488-494.
28. Bartolozzi C, Lencioni R, Caramella D, et al. Treatment of hepatocellular carcinoma with percutaneous ethanol injection: evaluation with contrast-enhanced MR imaging. AJR Am J Roentgenol. 1994;162: 827-831.
29. Yuen MF, Chan AO, Wong BC, et al. Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients. Am J Gastroenterol. 2003;98:1181-1185.
30. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona -2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430.
31. Ross BD, Chenevert TL, Rehemtulla A. Magnetic resonance imaging in cancer research. Eur J Cancer. 2002;38:2147-2156.
32. Hall DE, Moffat BA, Stojanovska J, et al. Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res. 2004;10:7852-7859.